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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: DREAMS shows excellent safety and efﬁcacy data with no death and
no scaffold thrombosis up to 3 years in the BIOSOLVE-I trial. Multi-modality im-
aging documented the absorption process and the uncaging aspect of this device
already at 6 months.
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Background: Bioresorbable stents have not been evaluated in a wide range of clinical
settings including ACS, STEMI, in-stent restenosis, SVG, and CTO. As of April 1st
2013, ABSORB BVS (BVS) became our default drug eluting device for patients at
our institution. The aim of this study is to evaluate the safety and efﬁcacy of this new
technology in a real-world setting.
Methods: Detailed patient characteristics and peri-procedural data are collected for
both patients receiving and not receiving a BVS and systematically entered in a
registry. In-hospital outcomes include MACE and bleeding complications and are
independently assessed by dedicated personnel.
Results: We will report on our ﬁrst year experience with BVS. Results are compared
to those in a group of patients treated concomitantly with other stent types. As of
March 31st 2013, 504 BVS have been implanted in 339 patients. Unadjusted MACE
(death, MI, Urgent PCI) rates were 2.0%, 2.4%, and 3.9% in patients treated with
BVS, DES and BMS, respectively.
Conclusions: Conclusions will be supported by the presented data and will reﬂect our
main ﬁndings. Preliminary results suggest comparable clinical outcomes with BVS
and DES in patients without contra-indication to drug-eluting devices.
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Background: The strut thickness and deliverability of BVS may increase procedural
time, contrast volume and ﬂuoroscopy time, especially in complex lesions.
Methods: In this study, 205 consecutive patients treated with either BVS (n¼99)
or drug eluting stent (DES) (n¼106) between May 2010 and May 2014 were
enrolled.
Results: The number of complex lesions (ACC/AHA lesion classiﬁcation type B2
and C) between BVS and DES group (84.7% vs. 90.6%, p¼0.01) was similar.
Pre and post-balloon dilatation were performed more frequently in the BVS
group compared to the DES group (97.1% vs. 79.4%, p< 0.01; 99.2% vs.
79.4%, p< 0.01, respectively). Maximum post dilatation balloon size was larger
and maximum inﬂation pressure was higher in the BVS compared to the DES
group (3.20.4 mm vs. 3.00.1 mm, p¼0.01; 21.15.1 atm vs. 19.25.0 atm,
p< 0.01, respectively), despite similar quantitative coronary angiogram (QCA)
results. Procedure time, amount of contrast and ﬂuoroscopy time in BVS group
were increased signiﬁcantly compared to those in the DES group (Table). In
multivariable analysis, after adjustment for SYNTAX score, chronic total oc-
clusion and lesion length by QCA, BVS use was identiﬁed as an independent
predictor of long procedure time (> 120 min.) (odds ratio: 4.9, 95% conﬁdence
interval: 2.67-9.36, p< 0.001).BVS
(patient n ¼ 99)
DES
(patient n¼ 106) P-value
Total procedure time, min 114.7  39.2 90.4  38.2 < 0.01
Total amount of contrast, ml 268.3  104.2 229.2  122.2 0.02
Total ﬂuoroscopy time, min 42.4  17.9 34.5  19.7 < 0.01Conclusions: Treating complex lesions with BVS requires longer procedure/
ﬂuoroscopy times and larger volumes of contrast as compared to DES implan-
tation to achieve similar procedural success rates and results. Improvements in
scaffold design may reduce the need for meticulous lesion predilatation with
dedicated devices and increase the spectrum of lesions amenable to treatment
with BVS.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteTCT-628
Safety and Efﬁcacy of Everolimus-Eluting Bioresorbable Vascular Scaffolds in
Complex Coronary Lesions
Suzanne de Waha1, Mohamed El-Mawardy1, Dmitriy S. Sulimov1, Takao Sato1,
Ralph Toelg1, Mohamed Abdel-Wahab1, Gert Richardt1
1Heart Center Bad Segeberg, Department of Cardiology and Angiology, Bad
Segeberg, Germany
Background: Everolimus-eluting bioresorbable vascular scaffolds (BVS) are
increasingly used in patients with complex coronary anatomies. However, data on
BVS in such indications are scarce. We thus sought to evaluate the safety and efﬁcacy
of ABSORB BVS in patients with complex coronary lesions.
Methods: Consecutive patients (n¼150) undergoing BVS implantation at a tertiary
care center entered a prospective registry. All patients underwent a detailed assessment
of clinical and procedural data. Clinical follow-up was performed 75 months
following the index procedure and was completed in all patients. Major adverse
cardiac events (MACE) included the occurrence of death, myocardial reinfarction,
stent thrombosis and target lesion revascularization. Complex coronary artery disease
was deﬁned as type B2 or C lesions. Device success was deﬁned as attainment of <
30% ﬁnal residual stenosis. Procedural success was deﬁned as device success without
periprocedural complications. Clinical success was deﬁned as procedural success and
absence of MACE within follow-up.
Results: Complex coronary lesions were present in 45.3% (n¼68) of patients.
Baseline characteristics such as age, gender or left ventricular ejection fraction did
not differ signiﬁcantly between patients with type B2/C lesions versus those with
type A/B1 lesions (all p>0.05). The number and length of BVS were higher in
patients with complex lesions (1.40.6 vs. 1.10.3, p< 0.001 / 3213 vs.
196mm, p< 0.001). Device success rate was high in both groups (97.1 vs.
97.6%, p¼1.00). At a relatively low rate of periprocedural complications (edge
dissection n¼7, side branch occlusion n¼2) procedural success did not differ
signiﬁcantly in patients with complex lesions in comparison to patients with non-
complex lesions (91.2 vs. 95.1%, p¼0.51). The majority of patients remained free
of angina within follow-up (85.3 vs. 92.7%, p¼0.19). MACE occurred in 1.5%
(n¼1) of patients with type B2/C lesions versus 7.3% (n¼6) with type A/B1 le-
sions (p¼0.13). Finally, clinical success was comparable in both groups (89.7 vs.
87.9%, p¼0.80).
Conclusions: BVS in complex coronary lesions appear to be promising in terms of
safety and efﬁcacy.
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Background: One of the hypothesized long-term clinical beneﬁts of Absorb BVS is
plaque regression (reduction in plaque volume) and stabilization (reduction in necrotic
and lipid composition). This study evaluates the effect of Absorb BVS on plaque size
and composition in a familial hypercholesterolemic (FH) swine model. We present
here the IVUS results at 1-year follow-up.
Methods: Ten-month-old female FH swine were fed an atherogenic diet for 21 weeks.
One week into the feeding, coronary arteries were balloon injured. Twenty weeks post
injury, intervened segments were imaged by IVUS for lesion progression and
randomly implanted with either Absorb BVS or metallic drug-eluting stents (DES,
XIENCE V) at a 2:1 ratio. All animals were imaged by angiography, IVUS and
OCT post implant and at an interim 1-year follow up.
Results: Plaque area (PA), %PA (as percentage of EEL area) and plaque tissue
composition were statistically similar for both device groups at pre and post implant
(baseline) demonstrating a good randomization of the study. At 1-year follow-up, the
implanted vessel (Absorb ¼ 23, DES ¼ 11) sizes remained unchanged. Change in the
mean PA from baseline to 1 year was -0.222.61mm2 for BVS and 1.151.36mm2
for DES (p ¼ 0.05). Changes of mean %PA were 112% and 76% for BVS and
DES (p¼0.07), respectively. There was a signiﬁcant decrease of %PA at MLD
(minimal lumen diameter) in BVS (-812%) compared to metallic DES (48%)
(p¼0.01). Plaque tissue characterization (iMAP-IVUS, Boston Scientiﬁc) revealed
that percentage changes of each plaque component were the same between the two
device groups with a decrease of ﬁbrotic and increase of lipid and necrotic
components.
Conclusions: At 1 year, plaque size trended towards reduction in Absorb but not
in metallic DES implanted vessels. Plaque tissue characterization suggests that
plaque stabilization has not occurred at 1 year; however, plaque stabilization is
hypothesized to be related to tissue replacement of polymeric struts and as such
expected during later stages of resorption. This hypothesis will be examined with
repeat in vivo imaging follow-up and histological evaluation in these animals at 2,
3, and 4 years.nts - Drug-eluting: Bioresorbable Scaffolds B183
